|
Type I Mucolipidosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
We report a type 1 sialidosis patient with a novel deletion mutation in NEU1 and compared the phenotypes within different ethnicities.
|
31371146 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessment of human epidermal growth factor receptor 2/neu gene amplification and expression as a biomarker for radiotherapy and hormonal-treated breast cancer patients in upper Egypt.
|
31603098 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bone metastases incidence and its correlation with hormonal and human epidermal growth factor receptor 2 neu receptors in breast cancer.
|
31603096 |
2020 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Assessment of human epidermal growth factor receptor 2/neu gene amplification and expression as a biomarker for radiotherapy and hormonal-treated breast cancer patients in upper Egypt.
|
31603098 |
2020 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Bone metastases incidence and its correlation with hormonal and human epidermal growth factor receptor 2 neu receptors in breast cancer.
|
31603096 |
2020 |
|
Type I Mucolipidosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Type 1 sialidosis (OMIM#256550) is a rare autosomal recessive lysosomal storage disease caused by a mutation in the NEU1 (OMIM * 608272) gene.
|
30635863 |
2019 |
|
Neuraminidase 1 deficiency
|
0.540 |
GeneticVariation
|
disease |
BEFREE |
Sialidosis is a rare lysosomal storage disease caused by an α-N-acetyl neuraminidase-1 deficiency due to mutations of the NEU1 gene (6p21).
|
30445145 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As a consequence of blocking Neu1, honokiol reduced the levels of sialic acid in the two subtypes of breast cancer.
|
31515676 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The link between Neuraminidase 1 (Neu1) and cancer development has been highlighted in numerous studies.
|
31515676 |
2019 |
|
Glomerular Filtration Rate
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
A catalog of genetic loci associated with kidney function from analyses of a million individuals.
|
31152163 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
As a consequence of blocking Neu1, honokiol reduced the levels of sialic acid in the two subtypes of breast cancer.
|
31515676 |
2019 |
|
Primary malignant neoplasm
|
0.090 |
Biomarker
|
group |
BEFREE |
The link between Neuraminidase 1 (Neu1) and cancer development has been highlighted in numerous studies.
|
31515676 |
2019 |
|
Noninfiltrating Intraductal Carcinoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
On the basis of the high frequency of estrogen receptor-positive (ER+) and HER2-positive (HER2+) DCIS, we hypothesized that this tumor type overexpresses HER2 protein without gene amplification and retrospectively investigated the HER2/neu gene status of 71 ER(+)HER2(+) DCIS, surgically removed during the 2007 to 2017 period, employing fluorescence in situ hybridization (FISH).
|
31192864 |
2019 |
|
Stomach Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Either TOB1-AS1 or NEU1 upregulation accelerated GC cell apoptosis, hampered proliferation, migration, and invasion.
|
31799657 |
2019 |
|
Malignant neoplasm of stomach
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Either TOB1-AS1 or NEU1 upregulation accelerated GC cell apoptosis, hampered proliferation, migration, and invasion.
|
31799657 |
2019 |
|
Tumor Progression
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
These findings provide evidence that Neu1 regulates cell growth and death, and facilitates cancer progression by modulating the expression levels of cadherins.
|
31515676 |
2019 |
|
Rheumatoid Arthritis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We decided to study the association of monocyte α-2,3-sialyltransferase 1 (ST3Gal-1), neuraminidase-3 (Neu3), α-2,6-sialyltransferase 1 (ST6Gal-1), and neuraminidase-1 (Neu1) levels with disease activity score 28 (DAS28) in human rheumatoid arthritis (RA), considering that mouse monocytes' sialic acid (SIA) levels relate to their phagocytosis and IgG binding ability.
|
30913115 |
2019 |
|
Lupus Erythematosus, Systemic
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Differential lectin binding, specifically Gal-1, to SLE T cells was explained by the increased gene expression ratio of sialyltransferases and neuraminidase 1 (<i>NEU1</i>), particularly by elevated ST6 beta-galactosamide alpha-2,6-sialyltranferase 1 (<i>ST6GAL1</i>)/<i>NEU1</i> and ST3 beta-galactoside alpha-2,3-sialyltransferase 6 (S<i>T3GAL6)</i>/<i>NEU1</i> ratios.
|
31509989 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Results revealed that miR-205 facilitated lipid accumulation by inhibiting NEU1 in NAFLD, suggesting that miR-205 might be a potential target for the therapeutic strategy for NAFLD.
|
31799678 |
2019 |
|
Infectious Lung Disorder
|
0.010 |
Biomarker
|
group |
BEFREE |
Neuraminidase 1-mediated desialylation of the mucin 1 ectodomain releases a decoy receptor that protects against <i>Pseudomonas aeruginosa</i> lung infection.
|
30429216 |
2019 |
|
Glycoprotein Storage Disease
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Lysosomal exocytosis is a ubiquitous process negatively regulated by neuraminidase 1 (NEU1), a sialidase mutated in the glycoprotein storage disease sialidosis.
|
31328155 |
2019 |
|
Type I Mucolipidosis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In this study, we used Sendai virus reprogramming to generate an induced pluripotent stem cell (iPSC) line carrying the A544G mutation combined with the 667-679 deletion of the NEU1 gene from a sialidosis patient.
|
29414417 |
2018 |
|
Mucolipidoses
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In this study, we used Sendai virus reprogramming to generate an induced pluripotent stem cell (iPSC) line carrying the A544G mutation combined with the 667-679 deletion of the NEU1 gene from a sialidosis patient.
|
29414417 |
2018 |
|
Carcinoma
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Detection of HER2/neu receptor overexpression and/or amplification is a prerequisite for efficient anti-HER2 treatment of breast and gastric carcinomas.
|
29530054 |
2018 |
|
Carcinogenesis
|
0.070 |
Biomarker
|
phenotype |
BEFREE |
OP was used because of its anticancer properties targeting mammalian neuraminidase 1 (Neu1) involved in multistage tumorigenesis.
|
29560107 |
2018 |